FCPA opinion shines light on reasonable expenses for foreign officials
By 
Kyle Brasseur2023-09-01T18:37:00
A Foreign Corrupt Practices Act (FCPA) review published by the Department of Justice (DOJ) last month offers further clarity around when the agency would determine expenses paid on behalf of a foreign official to be deemed “reasonable and bona fide.”
The opinion procedure release from Aug. 14—the first posted by the DOJ since January 2022—came in response to a request from a child welfare agency regarding whether its proposed payments on behalf of two foreign government officials visiting the United States to complete their post-adoption supervision requirements would violate the anti-bribery provisions of the FCPA.
Among the details of the request:
Related articles
-
News BriefFCPA opinion tackles government-authorized payments
A new Foreign Corrupt Practices Act review by the Department of Justice offers an example of when stipends paid to foreign government personnel would not be considered a violation of the anti-bribery provisions of the law.
-
News BriefOECD group questions Brazil’s momentum on anti-bribery
Brazil has made strides in its anti-bribery enforcement efforts, but a working group at the Organization for Economic Cooperation and Development is concerned the country doesn’t have the controls in place to sustain its progress.
-
PremiumSurvey: Tech gaps, third parties pose biggest ABAC threats
A recent survey conducted by Compliance Week and Morgan Lewis determined areas of insufficient resource support to combat bribery and corruption, along with trends in third-party due diligence.
More from Regulatory Enforcement
-
News BriefCFPB ends probe into Meta’s financial advertising practices
Meta says it is no longer under investigation by the U.S. Consumer Financial Protection Bureau (CFPB), the latest instance of the agency scaling back enforcement under President Donald Trump.
-
News BriefTexas sues Johnson & Johnson, Kenvue over alleged misleading marketing of Tylenol
Texas Attorney General Ken Paxton sued two pharmaceutical companies for ”deceptively marketing Tylenol to pregnant mothers” despite risks linked to autism. The filing came two days before HHS Secretary Robert F. Kennedy Jr. appeared to walk back the claims.
-
News BriefCFPB scraps bad-actor registry, citing cost-benefit issues
The Consumer Financial Protection Bureau shut down a registry of non-bank financial firms that broke consumer laws. The agency cites the costs being ”not justified by the speculative and unquantified benefits to consumers.”